Onur Baykara

Onur Baykara

Auto-generated profile, based on publicly available information

Onur Baykara

Department of Medical Biology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Turkey

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2005 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
MUM. Uzan
M. Uzan
TTTaner Tanriverdi
Taner Tanriverdi
OBO. Baykara
O. Baykara
AKA. Kafadar
A. Kafadar
GSG. Z. Sanus
G. Z. Sanus
NBN. Buyra
N. Buyra

1 January 2015 in Journal of Cancer
Verified
Journal Article
Open access
OBOnur Baykara
Onur Baykara
BBBurak Bakir
Burak Bakir
NBNur Buyru
Nur Buyru
KKKamil Kaynak
Kamil Kaynak
NDNejat Dalay
Nejat Dalay
Chromosomal alterations are frequent events in lung carcinogenesis and usually display regions of focal amplification containing several overexpressed oncogenes. Although gains and losses of chromosomal loci have been reported copy number changes of the individual genes have not been analyzed in lung cancer. In this study 22 genes were analyzed by MLPA in tumors and matched normal tissue samples from 82 patients with non-small cell lung cancer. Gene amplifications were observed in 84% of the samples. Chromosome 8 was found to harbor the most frequent copy number alterations. The most frequently amplified genes were ZNF703, PRDM14 and MYC on chromosome 8 and the BIRC5 gene on chromosome 17. The frequency of deletions were much lower and the most frequently deleted gene was ADAM9. Amplification of the ZNF703, PRDM14 and MYC genes were highly correlated suggesting that the genes displaying high copy number changes on chromosome 8 collaborate during lung carcinogenesis.

1 February 2005 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SYS. N. Yeni
S. N. Yeni
COC. Ozkara
C. Ozkara
NBNur Buyru
Nur Buyru
OBO. Baykara
O. Baykara
LHL. Hanoglu
L. Hanoglu
MUM. Uzan
M. Uzan

1 September 2014 in Gene
Verified
Journal Article
Closed access
MNMutlu Niyazoglu
Mutlu Niyazoglu
OBOnur Baykara
Onur Baykara
ABArzuhan Buyuker
Arzuhan Buyuker
PAPinar Aydoğdu
Pinar Aydoğdu
IOIlhan Onaran
Ilhan Onaran
GSGönül Kanigur Sultuybek
Gönül Kanigur Sultuybek

18 May 2010 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
OBOnur Baykara
Onur Baykara
ADAhmet Demirkaya
Ahmet Demirkaya
KKKamil Kaynak
Kamil Kaynak
STSerhan Tanju
Serhan Tanju
ATAlper Toker
Alper Toker
NBNur Buyru
Nur Buyru

20 September 2016 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
OBOnur Baykara
Onur Baykara
NDNejat Dalay
Nejat Dalay
KKKamil Kaynak
Kamil Kaynak
NBNur Buyru
Nur Buyru
Despite therapeutic advances, lung cancer remains one of the most common causes of cancer‐related deaths worldwide. The ZNF703 gene has been identified as the driver of the 8p11‐12 region and its amplification or overexpression has been associated with several types of cancers. It has also been shown that ZNF703 overexpression can activate the Akt/mTOR signaling pathway. The aim of our study was to investigate the role of the ZNF703 gene in association with Akt/mTOR activation in non‐small cell lung cancer (NSCLC). Expression levels in tumors and matched noncancerous tissue samples from 47 patients were analyzed by qRT‐PCR and the Akt phosphorylation levels were investigated by Western blotting. Our results show that ZNF703 is up‐regulated in 63.4% of NSCLC tumor samples. Althogh the correlation did not reach a statistically significant level Akt phosphorylation was increased in tumor tissues expressing high levels of ZNF703. The role of the ZNF703 gene has not been investigated in NSCLC. Our data show that ZNF703 may contribute to tumor development in NSCLC by activating the Akt/mTOR pathway.